Cargando…

Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study

BACKGROUND: Denosumab is a fully human monoclonal antibody that inhibits receptor activator of nuclear factor kappa-β ligand (RANKL). Previous reports have shown that denosumab treatment of osteoporotic patients decreases bone resorption and fracture risk, but there have been no clinical studies on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Yukio, Kamimura, Mikio, Ikegami, Shota, Mukaiyama, Keijiro, Uchiyama, Shigeharu, Taguchi, Akira, Kato, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678608/ https://www.ncbi.nlm.nih.gov/pubmed/26666998 http://dx.doi.org/10.1186/s12902-015-0077-3

Ejemplares similares

Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D(3) and alters values of parathyroid hormone, pentosidine, and bone metabolic markers
por: Kamimura, Mikio, et al.
Publicado: (2017)

Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women
por: Nakamura, Yukio, et al.
Publicado: (2017)

Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis
por: Kamimura, Mikio, et al.
Publicado: (2019)

Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
por: Kamimura, Mikio, et al.
Publicado: (2018)

A Case with Atypical Clinical Course Diagnosed as Osteoarthritis, Osteonecrosis, Subchondral Insufficiency Fracture, or Rapidly Destructive Coxopathy
por: Nakamura, Yukio, et al.
Publicado: (2014)

The Pathophysiology and Progression of Hip Osteoarthritis Accompanied with Joint Pain are Potentially Due to Bone Alterations - Follow-up Study of Hip OA Patients
por: Kamimura, Mikio, et al.
Publicado: (2014)

The Pathophysiology of Primary Hip Osteoarthritis may Originate from Bone Alterations
por: Kamimura, Mikio, et al.
Publicado: (2013)

Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment
por: Nakamura, Yukio, et al.
Publicado: (2017)

A case series of pregnancy- and lactation-associated osteoporosis and a review of the literature
por: Nakamura, Yukio, et al.
Publicado: (2015)

Knee Joint Pain Potentially Due to Bone Alterations in a Knee Osteoarthritis Patient
por: Komatsu, Masatoshi, et al.
Publicado: (2014)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment
por: Nakamura, Yukio, et al.
Publicado: (2018)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

Delayed wound healing after tooth extraction and self-reported kyphosis in Japanese men and women
por: Taguchi, Akira, et al.
Publicado: (2016)

Associations of self-reported height loss and kyphosis with vertebral fractures in Japanese women 60 years and older: a cross-sectional survey
por: Kamimura, Mikio, et al.
Publicado: (2016)

Joint Pain Undergoes a Transition in Accordance with Signal Changes of Bones Detected by MRI in Hip Osteoarthritis
por: Kamimura, Mikio, et al.
Publicado: (2013)

Denosumab significantly improves lumbar spine bone mineral density more in treatment-naïve than in long-term bisphosphonate-treated patients
por: Suzuki, Takako, et al.
Publicado: (2018)

Bone alterations are associated with ankle osteoarthritis joint pain
por: Nakamura, Yukio, et al.
Publicado: (2016)

Monthly minodronate inhibits bone resorption to a greater extent than does monthly risedronate
por: Kamimura, Mikio, et al.
Publicado: (2016)

Efficacy of denosumab therapy for neurofibromatosis type 1 with osteoporosis and history of fractures: a case report
por: Uehara, Masashi, et al.
Publicado: (2018)

Efficacy of Denosumab for Osteoporosis in Two Patients with Adult-Onset Still’s Disease—Denosumab Efficacy in Osteoporotic Still’s Disease Patients
por: Kumaki, Daiki, et al.
Publicado: (2018)

Risk factors of adjacent vertebral collapse after percutaneous vertebroplasty for osteoporotic vertebral fracture in postmenopausal women
por: Takahara, Kenji, et al.
Publicado: (2016)

Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients
por: Suzuki, Takako, et al.
Publicado: (2017)

Comparison in bone turnover markers during early healing of femoral neck fracture and trochanteric fracture in elderly patients
por: Ikegami, Shota, et al.
Publicado: (2009)

Early Changes in Bone Specific Turnover Markers During the Healing Process After Vertebral Fracture
por: Hashidate, Hiroyuki, et al.
Publicado: (2011)

Anti-Nociceptive Effects of Elcatonin Injection for Postmenopausal Women with Back Pain: A Randomized Controlled Trial
por: Ikegami, Shota, et al.
Publicado: (2010)

Unexpected rapid increase in bone mineral density by bisphosphonate therapy after multiple spinal fractures: a case report
por: Koiwai, Hidefumi, et al.
Publicado: (2019)

Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment
por: Nakamura, Yukio, et al.
Publicado: (2017)

Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis
por: Nakamura, Yukio, et al.
Publicado: (2017)

Effect of teriparatide (rh-PTH 1–34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: A retrospective comparative study
por: Iwata, Akira, et al.
Publicado: (2017)

Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

Perforation Rates of Cervical Pedicle Screw Insertion by Disease and Vertebral Level
por: Uehara, Masashi, et al.
Publicado: (2010)

Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients
por: Suzuki, Takako, et al.
Publicado: (2018)

Future of bisphosphonates and denosumab for men with advanced prostate cancer
por: Iranikhah, Maryam, et al.
Publicado: (2014)

Can denosumab be a substitute, competitor, or complement to bisphosphonates?
por: Kim, Su Young, et al.
Publicado: (2017)

Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan
por: Liu, Fang-Chun, et al.
Publicado: (2023)

Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2018)

Adequate nutrition status important for bone mineral density improvement in a patient with anorexia nervosa
por: Nakamura, Yukio, et al.
Publicado: (2018)

Contrasting PTH Response of Denosumab Use in Dialysis Patients: A Report of 2 Cases
por: Jang, Soo Min, et al.
Publicado: (2020)

BISPHOSPHONATE-INDUCED MAXILLOFACIAL OSTEONECROSIS IN OSTEOPOROTIC INDIVIDUALS
por: da Silva Santos, Paulo Sérgio, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0gl0n4ljsr70gge8c8d5kushoc